Elderly mice suffering from age-related heart disease saw a significant improvement in cardiac function after being treated with the FDA-approved drug rapamycin for just three months. The research, led by a team of scientists at the Buck Institute for Research on Aging, shows how rapamycin impacts mammalian tissues, providing functional insights and possible benefits for a drug that has been shown to extend the lifespan of mice as much as 14 percent. There are implications for human health in the research appearing online in Aging Cell: heart disease is the leading cause of death in the U.S., claiming nearly 600,000 lives per year.
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality in over a decade and should be added to standard treatment, according to lead author Professor Svend Aage Mortensen (Copenhagen, Denmark).
Scientific collaborators from Yale School of Medicine and University College London (UCL) have uncovered the molecular pathway by which new arteries may form after heart attacks, strokes and other acute illnesses bypassing arteries that are blocked. Their study appears in the April 29 issue of Developmental Cell.
Atherosclerosis ? sometimes called “hardening of the arteries” ? is a leading cause of death and morbidity in Western countries. A cell-permeable peptide containing the NF-?B nuclear localization sequence (NLS) shows promise as a potential agent in controlling the development of atherosclerotic disease. This study is published in the May 2013 issue of The American Journal of Pathology.
L-carnitine significantly improves cardiac health in patients after a heart attack, say a multicenter team of investigators in a study published today in Mayo Clinic Proceedings. Their findings, based on analysis of key controlled trials, associate L-carnitine with significant reduction in death from all causes and a highly significant reduction in ventricular arrhythmias and anginal attacks following a heart attack, compared with placebo or control.
A clot-busting therapy may benefit some heart attack patients who cannot have immediate angioplasty, according to research presented today at the American College of Cardiology’s 62nd Annual Scientific Session.
A single dose of an investigational anti-inflammatory drug called inclacumab considerably reduces damage to heart muscle during angioplasty (the opening of a blocked artery), according to a recent international clinical trial spearheaded by Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, affiliated with the University of Montreal. Presented today in San Francisco at the prestigious American cardiology conference, these findings show great promise.
Scientists investigating how certain genes affect an individual’s risk of developing coronary heart disease have identified a new therapeutic target, according to research published today in The American Journal of Human Genetics.
Using two different compounds they developed, scientists from the Florida campus of The Scripps Research Institute (TSRI) have been able to show in animal models that inhibiting a specific enzyme protects heart cells and surrounding tissue against serious damage from heart attacks. The compounds also protect against additional injury from restored blood flow after an attack, a process known as reperfusion.
The risk of ischaemic heart disease ? a disease affecting some 150,000 Danes ? is three times higher in persons with high levels of the so-called ‘ugly’ cholesterol. This is the finding of a new study of 73,000 Danes, which is shedding light on a long debate on this topic. The results have just been published in the Journal of the American College of Cardiology.